Replies to post #32355 on Biotech Values

[DewDiligence]

Hi Praveen. The Xigris article I just posted mentioned Protherics (about 3/4 of the way down):

>>
Worse still for Xigris, although the threat of Chiron/Pharmacia's tifacogin has receded, competition may soon be on its way in other forms, including ICOS/Suntory's Pafase, Abbott's afelimomab, and Protherics' CytoTAb target tumor necrosis factor.
<<

I’ll have to learn something about these programs to see if they are serious candidates in the sepsis arena. Regards, Dew

[gofishmarko]

Re : Sepsis

I haven't followed the anti-TNF / sepsis area closely but recall reading that it is not expected to be a dramatic answer to the sepsis problem. I think the contribution of TNF to the condition probably varies between cases and between time points within a particular case.

My interest follows from recent revelations that SCLN's Zadaxin is being used in China for "perioperative infections" , which I think can be safely translated as meaning sepsis , although in the case of Zadaxin I presume it's being given as a prophylactic measure prior to intensive surgical procedures.

Two sources of additional info on sepsis :

http://www.sccm.org/SCCM/Professional+Resources/Sepsis+Information/

tiny version : http://tinyurl.com/g9a6k

and this free online journal that can be accessed after registration:

http://www.advancesinsepsis.com/index.aspx